Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

医学 内科学 美罗华 布仑妥昔单抗维多汀 耐火材料(行星科学) 淋巴瘤 肿瘤科 临床试验 临床研究阶段 霍奇金淋巴瘤 天体生物学 物理
作者
Franck Morschhauser,Ian W. Flinn,Ranjana H. Advani,Laurie H. Sehn,Catherine Diefenbach,Kathryn S. Kolibaba,Oliver W. Press,Gilles Salles,Hervé Tilly,Andy I. Chen,Sarit Assouline,Bruce D. Cheson,Martin Dreyling,Anton Hagenbeek,Pier Luigi Zinzani,Surai Jones,Ji Cheng,Dan Lü,Elicia Penuel,Jamie Hirata
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:6 (5): e254-e265 被引量:249
标识
DOI:10.1016/s2352-3026(19)30026-2
摘要

Background Antibody–drug conjugates (ADCs) polatuzumab vedotin (pola) and pinatuzumab vedotin (pina) showed clinical activity and tolerability in phase 1 trials. The aim of this multicentre, open-label, phase 2 study was to compare rituximab plus pola (R-pola) or pina (R-pina) in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. Methods In this phase 2 randomised study at 39 investigational sites in six countries, patients were randomly assigned (1:1), by use of a dynamic hierarchical randomisation scheme, to receive R-pola or R-pina (375 mg/m2 rituximab plus 2·4 mg/kg ADCs) every 21 days until disease progression or unacceptable toxicity up to 1 year. Treatment allocations were not masked to the investigator, patients or sponsor after the patients were enrolled and randomly assigned. The primary objectives were safety and tolerability, and antitumour response. The study is registered with ClinicalTrials.gov, number NCT01691898, and is closed to accrual. Findings 81 patients with diffuse large B-cell lymphoma and 42 with follicular lymphoma were recruited between Sept 27, 2012, and Oct 10, 2013, and were assigned to treatment. 81 patients with diffuse large B-cell lymphoma and 41 patients with follicular lymphoma were eligible for analysis. Of the 42 patients with diffuse large B-cell lymphoma who received R-pina, 25 (60%, 95% CI 43–74) achieved an objective response and 11 (26%, 95% CI 14–42) achieved a complete response. Of the 39 patients in this cohort who received R-pola, 21 (54%, 95% CI 37–70) achieved an objective response, and eight (21%, 95% CI 9–36) achieved a complete response. Of the 21 patients in the follicular lymphoma cohort who received R-pina, 13 (62%, 95% CI 38–82) achieved an objective response, and one (5%, 95% CI 0·1–24) achieved a complete response. Of the 20 patients in this cohort who received R-pola, 14 (70%, 95% CI 46–88) achieved an objective response, and nine (45%, 95% CI 23–68) achieved a complete response. In the diffuse large B-cell lymphoma cohort, grade 3–5 adverse events occurred in 33 (79%) of 42 patients receiving R-pina (most common were neutropenia [29%] and hyperglycaemia [10%]; nine [21%] grade 5 adverse events, five of which were infection-related), and in 30 (77%) of 39 patients receiving R-pola (most common were neutropenia [23%], anaemia [8%] and diarrhoea [8%]; no grade 5 adverse events). In the follicular lymphoma cohort, grade 3–5 adverse events occurred in 13 (62%) of 21 patients receiving R-pina (most common were neutropenia [29%] and hyperglycaemia [14%]; no grade 5 adverse events) and in ten (50%) of 20 patients receiving R-pola (most common were neutropenia [15%] and diarrhoea [10%]; one grade 5 adverse event). Interpretation R-pina and R-pola are potential treatment options in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. Pola was selected by the study funder for further development in non-Hodgkin lymphoma, partly because of longer durations of response than pina, and an overall benefit–risk favouring R-pola. Funding F Hoffmann-La Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ivy_Leo完成签到 ,获得积分10
1秒前
小马甲的应助被null采纳,获得10
1秒前
tttttttt完成签到 ,获得积分10
1秒前
沉默发布了新的文献求助10
1秒前
逢坂大河的应助被zzhui采纳,获得10
2秒前
Tsing_if完成签到 ,获得积分10
3秒前
4秒前
stone发布了新的文献求助10
4秒前
安详绿草完成签到,获得积分10
5秒前
xfy发布了新的文献求助80
5秒前
AireenBeryl531的应助被zizi采纳,获得10
6秒前
英俊的铭的应助被123采纳,获得10
7秒前
万能图书馆的应助被leilei采纳,获得10
7秒前
tx的应助被有魅力机器猫采纳,获得10
9秒前
周周发布了新的文献求助10
9秒前
高挑的葵阴完成签到,获得积分10
10秒前
柏笙笑完成签到 ,获得积分10
10秒前
小情绪发布了新的文献求助10
10秒前
无花果的应助被坚强孤容采纳,获得10
11秒前
TwistZz发布了新的文献求助10
12秒前
12秒前
Maestro_S的应助被科研通管家采纳,获得10
12秒前
唐唐完成签到,获得积分10
12秒前
12秒前
Subwaid的应助被科研通管家采纳,获得10
12秒前
12秒前
隐形曼青的应助被科研通管家采纳,获得10
13秒前
邵洋完成签到,获得积分10
13秒前
Firsterchao的应助被科研通管家采纳,获得10
13秒前
orixero的应助被科研通管家采纳,获得10
13秒前
molihuakai的应助被科研通管家采纳,获得10
13秒前
molihuakai的应助被科研通管家采纳,获得10
13秒前
13秒前
小蘑菇的应助被科研通管家采纳,获得10
13秒前
CAOHOU的应助被drizzle采纳,获得10
13秒前
fantasy的应助被科研通管家采纳,获得10
14秒前
每天都好困完成签到,获得积分10
14秒前
ding的应助被科研通管家采纳,获得10
14秒前
共享精神的应助被科研通管家采纳,获得10
14秒前
小蘑菇的应助被科研通管家采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186734
求助须知:如何正确求助?哪些是违规求助? 9575007
关于积分的说明 21839114
捐赠科研通 7784289
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559206
邀请新用户注册赠送积分活动 2481611